Pfizer, an American multinational pharmaceutical corporation, agreed to acquire an 8.1% stake in Valneva, a vaccine company focused on developing life-saving vaccines, for $95m. “Pfizer’s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva’s vaccine expertise. This subscription agreement will contribute to our investment in the Phase 3 study while limiting the impact on our cash position. Lyme disease is spreading and represents a high unmet medical need which impacts the lives of millions of people in the Northern Hemisphere," Thomas Lingelbach, Valneva CEO.